After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Crunch time approaches for UroGen.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
Herthena-Lung02 data are an ASCO shocker.
